BridgeMD
Randomized double blind double dummy control trial comparing the safety and efficacy of rituximab versus oral cyclophosphamide in severe forms of mucous membrane pemphigoid - (RITUX-MMP)
EU CTIS ID: 2024-514885-38-00
What this study is testing
To assess the superiority of rituximab compared to cyclophosphamide used in combination therapy with dapsone, to achieve CR or partial remission (PR) (corresponding in clinical practice to "almost Complete Remission") of disease activity at Month 12, in patients with severe forms of MMP
- Therapeutic confirmatory (Phase III)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- 1. Male or female patients aged ≥18 years old and ≤ 85 years old with a newly diagnosed or previously diagnosed severe MMP diagnosed according to the International MMP Consensus (Chan 2002) on the following criteria: Clinical features: Blisters or erosions predominantly affecting any or all mucous membranes (oral, nasal, pharyngeal, laryngeal, anal, genital, or esophageal,) with or without clinically observable scarring. Ocular involvement includes conjunctival inflammation, shortening of fornices, symblepharon, ankyloblepharon, entropion, trichiasis and corneal neovascularisation. Patients with skin involvement must not have more than 2 out of the 4 clinical criteria for bullous pemphigoid (BP) proposed by the French group (Vaillant L et al,1998; Joly P et al. 2004) Direct Immunofluorescence (DIF): Linear deposits of IgG, IgA and/or C3 on the BMZ by DIF of patient's skin or mucous membrane NB: Patients with pure ocular involvement can be included despite a negative DIF performed on the oral mucosa and despite the absence of suggestive histological picture if ophtalmologists consider the clinical ocular features are typical of MMP and that performing a biopsy on an inflammatory conjunctiva is risky. Histology: Sub epithelial blister with or without significant leukocyte infiltrate by standard histology of skin or mucosal lesions, when the skin or mucosal biopsy is possible and appropriate.
- 2. MMP is defined as "severe" in patients with: Sight-threatening ocular disease, and/or Potentially life-threatening laryngeal, tracheal or oesophageal stenosis, and/or Involvement of a mucosal site where there is a risk of scarring stenosis (larynx, trachea, esophagus, anus, foreskin, vagina…) and/or DocuSign Envelope ID: 50295166-4E99-49C6-987F-578D0A3FC8AE XML File Identifier: aaTJ0TmguGQxRA0B9cisw43tfaI= Page 15/39 More than one mucosal site involved and/or Mucosal involvement (including exclusive but severe oral involvement defined as an oral MMP DAI score > 10), and/or Skin or oral involvement, which have not achieved control of disease activity despite a one month treatment with dapsone at the maximum dose tolerated or by salazopyrine in patents intolerant to dapsone or having a contra indication to dapsone. or for patients with sightthreatening ocular disease, and/or potentially life-threatening laryngeal, tracheal or oesophageal stenosis, without previous treatment by dapsone
- 3. Patient having read and understood the information letter and signed the Informed Consent Form
- 4. Patient with updated vaccinations. It is recommended that a patient's vaccination record and the need for immunization prior to study entry be carefully investigated.
- 5. For women who are not postmenopausal (≥12 months of non− therapy-induced amenorrhoea) or surgically sterile (absence of ovaries and/or uterus) and who do not plan on having children anymore: agreement to remain abstinent or use two adequate methods of contraception, including at least one method with a failure rate of <1% per year, during the treatment period and for at least 12 months after the last dose of study treatment. Abstinence is acceptable only if it is in line with the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not acceptable methods of contraception. Barrier methods must always be supplemented with the use of a spermicide. For men: Surgical sterility or agreement to remain abstinent or use a condom during the treatment period and for at least 12 months after the last dose of study treatment and agreement to refrain from donating sperm during this same period. Abstinence is only acceptable if it is in line with the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not acceptable methods of contraception.
- 6. Patient agreement to avoid excessive exposure to sunlight during study participation
You likely can't join if
- 1. Patient < 18 years old or > 85 years old
- 10. Past history of malignant disease in the previous 5 years, or current progressive malignant disease, except basal cell carcinoma, and squamous cell carcinoma of the skin that have been treated or excised and cured, in situ cervix carcinoma, or any situation in which the oncologist in charge of the patient considers that risk of evolution of severe localisation(s) of MMP is higher than oncologic risk of cyclophosphamide and rituximab.
- 11. Anaemia (haemoglogin < 10 g/ dL ), neutropoenia (<1000/mm3), Persistent lymphopoenia (<800/mm3), thrombopoenia (<100 000/mm3)
- 12. Positive test results for hepatitis B surface antigen , hepatitis B core, antibody , or hepatitis C virus serology at screening
- 13. Liver insufficiency, major renal insufficiency (creatinin clearance ≤ 30 ml/min)
- 14. Currently active alcohol or drug abuse, or history of alcohol or drug abuse within 24 weeks prior to screening
See the full eligibility criteria
Who can join
- 1. Male or female patients aged ≥18 years old and ≤ 85 years old with a newly diagnosed or previously diagnosed severe MMP diagnosed according to the International MMP Consensus (Chan 2002) on the following criteria: Clinical features: Blisters or erosions predominantly affecting any or all mucous membranes (oral, nasal, pharyngeal, laryngeal, anal, genital, or esophageal,) with or without clinically observable scarring. Ocular involvement includes conjunctival inflammation, shortening of fornices, symblepharon, ankyloblepharon, entropion, trichiasis and corneal neovascularisation. Patients with skin involvement must not have more than 2 out of the 4 clinical criteria for bullous pemphigoid (BP) proposed by the French group (Vaillant L et al,1998; Joly P et al. 2004) Direct Immunofluorescence (DIF): Linear deposits of IgG, IgA and/or C3 on the BMZ by DIF of patient's skin or mucous membrane NB: Patients with pure ocular involvement can be included despite a negative DIF performed on the oral mucosa and despite the absence of suggestive histological picture if ophtalmologists consider the clinical ocular features are typical of MMP and that performing a biopsy on an inflammatory conjunctiva is risky. Histology: Sub epithelial blister with or without significant leukocyte infiltrate by standard histology of skin or mucosal lesions, when the skin or mucosal biopsy is possible and appropriate.
- 2. MMP is defined as "severe" in patients with: Sight-threatening ocular disease, and/or Potentially life-threatening laryngeal, tracheal or oesophageal stenosis, and/or Involvement of a mucosal site where there is a risk of scarring stenosis (larynx, trachea, esophagus, anus, foreskin, vagina…) and/or DocuSign Envelope ID: 50295166-4E99-49C6-987F-578D0A3FC8AE XML File Identifier: aaTJ0TmguGQxRA0B9cisw43tfaI= Page 15/39 More than one mucosal site involved and/or Mucosal involvement (including exclusive but severe oral involvement defined as an oral MMP DAI score > 10), and/or Skin or oral involvement, which have not achieved control of disease activity despite a one month treatment with dapsone at the maximum dose tolerated or by salazopyrine in patents intolerant to dapsone or having a contra indication to dapsone. or for patients with sightthreatening ocular disease, and/or potentially life-threatening laryngeal, tracheal or oesophageal stenosis, without previous treatment by dapsone
- 3. Patient having read and understood the information letter and signed the Informed Consent Form
- 4. Patient with updated vaccinations. It is recommended that a patient's vaccination record and the need for immunization prior to study entry be carefully investigated.
- 5. For women who are not postmenopausal (≥12 months of non− therapy-induced amenorrhoea) or surgically sterile (absence of ovaries and/or uterus) and who do not plan on having children anymore: agreement to remain abstinent or use two adequate methods of contraception, including at least one method with a failure rate of <1% per year, during the treatment period and for at least 12 months after the last dose of study treatment. Abstinence is acceptable only if it is in line with the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not acceptable methods of contraception. Barrier methods must always be supplemented with the use of a spermicide. For men: Surgical sterility or agreement to remain abstinent or use a condom during the treatment period and for at least 12 months after the last dose of study treatment and agreement to refrain from donating sperm during this same period. Abstinence is only acceptable if it is in line with the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not acceptable methods of contraception.
- 6. Patient agreement to avoid excessive exposure to sunlight during study participation
- 7. Patient able to comply with the study protocol, in the investigator's judgment
- 8. Patient affiliated with, or beneficiary of a social security category
What rules you out
- 1. Patient < 18 years old or > 85 years old
- 10. Past history of malignant disease in the previous 5 years, or current progressive malignant disease, except basal cell carcinoma, and squamous cell carcinoma of the skin that have been treated or excised and cured, in situ cervix carcinoma, or any situation in which the oncologist in charge of the patient considers that risk of evolution of severe localisation(s) of MMP is higher than oncologic risk of cyclophosphamide and rituximab.
- 11. Anaemia (haemoglogin < 10 g/ dL ), neutropoenia (<1000/mm3), Persistent lymphopoenia (<800/mm3), thrombopoenia (<100 000/mm3)
- 12. Positive test results for hepatitis B surface antigen , hepatitis B core, antibody , or hepatitis C virus serology at screening
- 13. Liver insufficiency, major renal insufficiency (creatinin clearance ≤ 30 ml/min)
- 14. Currently active alcohol or drug abuse, or history of alcohol or drug abuse within 24 weeks prior to screening
- 15. Patients with positive blood test for HIV
- 16. Inherited or acquired severe immune deficiency
- 17. Current active systemic infection which has required oral antibiotic treatment within 2 weeks prior to randomization
- 18. Infection having required hospitalization, or IV antibiotic treatment within 4 weeks prior to enrollment
- 19. Past history of severe infection such as fasciitis, osteomyelitis septic arthritis during the year prior to enrollment. Entry into this study may be reconsidered once the infection has fully resolved
- 2. Non-consenting patient or patient who cannot be followed regularly
- 20. Evidence of any new or uncontrolled concomitant disease that, in the investigator's judgment, would preclude patient participation, including but not limited to nervous system, renal, hepatic, endocrine, malignant, or gastrointestinal disorders
- 21. Any concomitant chronic condition that required prolonged treatment with oral or systemic corticosteroids with a prednisone / prednisolone dose >20 mg/day
- 22. Major surgery within 4 weeks prior to randomization, excluding diagnostic surgery.
- 23. Patients having received immunosuppressive treatment (such as cyclosporine, mycophenolate mofetil, azathioprine) given at an effective dose for any other condition than MMP, or any other treatment that might potentially be active on MMP lesions (anti-TNF) within 4 weeks prior to baseline
- 24. Treatment with intravenous immunoglobulins, plasmapheresis, or other similar procedure within 8 weeks prior to randomization
- 25. Recent treatment: with cyclophosphamide (<2 months) or rituximab (<6 months)
- 26. Previous treatment with a B cell−targeted therapy other than rituximab (e.g., anti-CD20, anti-CD22, or anti-BLyS) during the last 6 months
- 27. Treatment with a live or attenuated vaccine within 28 days prior to randomization
- 28. Contraindication to MABTHERA 500 mg concentrate for solution for infusion
- 29. Contraindication to ENDOXAN 50 mg, tablets
- 3. Patients with only MMP sequelae (stenosis, fibrosis, without inflammation or disease activity)
- 30. Contraindication to methylprednisolone marketed as 120 mg powder for injectable solution pharmaceutical form
- 31. Contraindication to paracetamol marketed as 10 mg/ml solution for infusion pharmaceutical form
- 32. Contraindication to dexchlorphéniramine maleate marketed as 5 mg/ injectable solution pharmaceutical form
- 33. Contraindication to sodium chloride marketed as 0,9% sodium chloride solution for infusion pharmaceutical form
- 34. Contraindication to glucose marketed as 5% glucose solution for infusion pharmaceutical form
- 35. Lactose and/or sucrose intolerance
- 36. Lack of peripheral venous access
- 37. Women pregnant or lactating, or intending to become pregnant during and for 12 months following the study. Women who are not postmenopausal (≥ 12 months of non−therapy-induced amenorrhea) or surgically sterile must have a negative result from a serum pregnancy test within 1 week prior to randomization.
- 38. Patients who plan on having children (due to the risk of amenorrhoea/azoospermia related to cyclophosphamide) and due to the long retention time of rituximab in B cells depleted patients, women of childbearing potential should use effective contraceptive methods during and for 12 months following treatment with MABTHERA or Cyclophosphamide
- 39. Participation in another interventional clinical trial within 28 days prior to randomization and during the study
- 4. Patients with Brunsting Perry pemphigoid and exclusive skin lesions without mucosal involvement
- 40. Person deprived of liberty by administrative or judicial decision or placed under judicial protection (guardianship or supervision)
- 5. Karnofsky index < 50%
- 6. Unstable angina or advanced ischemic cardiopathy (extensive myocardial infarction within the last 3 months or post-infarction heart failure)
- 7. Severe heart failure (NYHA Class III or IV) or severe uncontrolled cardiac disease
- 8. Uncontrolled cardiac rhythm disorders
- 9. Severe bronchial obstruction
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.